Global Bacterial Vaginosis Drugs Market 2017-2021

細菌性膣病治療薬の世界市場2017-2021:経口薬、局所薬

◆タイトル:Global Bacterial Vaginosis Drugs Market 2017-2021
◆商品コード:IRTNTR14695
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2017年9月12日
◆ページ数:71
◆資料形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:Healthcare and Life Sciences
◆販売価格オプション(消費税別)
Single User(1名利用)USD3,500 ⇒換算¥395,500見積依頼/購入/質問フォーム
Five User(~5名利用)USD4,000 ⇒換算¥452,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD5,000 ⇒換算¥565,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

Technavio社が発行した当調査レポートでは、細菌性膣病治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、細菌性膣病治療薬の世界市場規模及び予測、地域別分析/市場規模、市場の成長要因、市場の課題、製品パイプライン分析、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。Technavio社は細菌性膣病治療薬の世界市場が2017-2021年期間中に年平均2.16%成長すると予測しています。当レポート上に記載されている主な企業はBayer、Pfizer、Sanofi、Starpharma Holdings等です。

About Bacterial Vaginosis Drugs
BV is a vaginal disease caused due to complex alteration of flora present in the vagina. Antibacterial drugs are used for the treatment of BV, some of the most common drugs used for the treatment of the disease include Metronidazole, Clindamycin, and Tinidazole. The drugs are used in both oral and topical forms. Two types of bacteria are found in the genital parts of the women, termed as good bacteria and bad bacteria. The good bacteria present in the vagina are lactobacilli, which prevents the growth of bad bacteria.

Technavio’s analysts forecast the global bacterial vaginosis drugs market to grow at a CAGR of 2.16% during the period 2017-2021.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global bacterial vaginosis drugs market for 2017-2021. The report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio’s report, Global Bacterial Vaginosis Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• Bayer
• Pfizer
• Sanofi
• Starpharma Holdings

[Other prominent vendors]
• Allergan
• AstraZeneca
• Cardinal Health
• Mylan
• Novartis
• Sun Pharmaceutical Industries
• Symbiomix Therapeutics
• Teva Pharmaceutical Industries

[Market driver]
• Unmet demand in BV treatment market
• For a full, detailed list, view our report

[Market challenge]
• Development of resistance against antibiotics
• For a full, detailed list, view our report

[Market trend]
• Growing awareness about controlled use of antibiotics
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?

*** You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【資料の目次】

Table of Contents
PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction
• Market outline

PART 05: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis

PART 06: Pipeline analysis

PART 07: Market segmentation by ROA
• Oral
• Topical

PART 08: Geographical segmentation
• BV drugs market in Americas
• BV drugs market in EMEA
• BV drugs market in APAC

PART 09: Decision framework

PART 10: Drivers and challenges
• Market drivers
• Market challenges

PART 11: Market trends
• Growing awareness about controlled use of antibiotics
• Rising popularity of topical drugs and other treatment options such as probiotic drugs

PART 12: Vendor landscape

PART 13: Key vendor analysis
• Bayer
• Pfizer
• Sanofi
• Starpharma Holdings
• Other prominent vendors

PART 14: Appendix
• List of abbreviations

[List of Exhibits] 
Exhibit 01: Risk factors for BV
Exhibit 02: Symptoms, diagnosis, and treatment of BV
Exhibit 03: Global BV drugs market snapshot
Exhibit 04: Global BV drugs market 2016-2021 ($ millions)
Exhibit 05: Opportunity analysis of global BV drugs market
Exhibit 06: Five forces analysis
Exhibit 07: Key pipeline molecules by vendors
Exhibit 08: Global BV drugs market: Key trials
Exhibit 09: Global BV drugs market by ROA 2016
Exhibit 10: Global BV drugs market by ROA 2016 and 2021
Exhibit 11: Basis for the choice of routes
Exhibit 12: Advantages and disadvantages of oral route of drug administration
Exhibit 13: Global BV oral drugs market 2016-2021 ($ millions)
Exhibit 14: Advantages and disadvantages of topical drugs
Exhibit 15: Global BV topical drugs market 2016-2021 ($ millions)
Exhibit 16: Segmentation of global BV drugs market by geography 2016 and 2021
Exhibit 17: Global BV drugs market revenue by geography 2016-2021 ($ millions)
Exhibit 18: Market scenario in Americas
Exhibit 19: BV drugs market in Americas 2016-2021 ($ millions)
Exhibit 20: Market scenario in EMEA
Exhibit 21: BV drugs market in EMEA 2016-2021 ($ millions)
Exhibit 22: Prevalence rate of BV in Europe
Exhibit 23: Market scenario in APAC
Exhibit 24: BV drugs market in APAC 2016-2021 ($ millions)
Exhibit 25: Complications associated with BV
Exhibit 26: Pregnancy complications due to BV
Exhibit 27: Symptoms of PID
Exhibit 28: Sociocultural factors preventing females from quality health services
Exhibit 29: Women health programs
Exhibit 30: Resistance for clindamycin
Exhibit 31: Major causes of antibiotic resistance
Exhibit 32: Competitive structure analysis of global BV drugs market 2016
Exhibit 33: Bayer: Key highlights
Exhibit 34: Bayer: Strength assessment
Exhibit 35: Bayer: Strategy assessment
Exhibit 36: Bayer: Opportunity assessment
Exhibit 37: Pfizer: Key highlights
Exhibit 38: Pfizer: Strength assessment
Exhibit 39: Pfizer: Strategy assessment
Exhibit 40: Pfizer: Opportunity assessment
Exhibit 41: Key highlights
Exhibit 42: Sanofi: Strength assessment
Exhibit 43: Sanofi: Strategy assessment
Exhibit 44: Sanofi: Opportunity assessment
Exhibit 45: Starpharma: Key highlights
Exhibit 46: Starpharma: Strength assessment
Exhibit 47: Starpharma: Strategy assessment
Exhibit 48: Starpharma: Opportunity assessment



【掲載企業】

Bayer, Pfizer, Sanofi, Starpharma Holdings, Allergan, AstraZeneca, Cardinal Health, Mylan, Novartis, Sun Pharmaceutical Industries, Symbiomix Therapeutics, and Teva Pharmaceutical Industries.


★調査レポート[細菌性膣病治療薬の世界市場2017-2021:経口薬、局所薬] (Global Bacterial Vaginosis Drugs Market 2017-2021 / IRTNTR14695)販売に関する免責事項
[細菌性膣病治療薬の世界市場2017-2021:経口薬、局所薬] (Global Bacterial Vaginosis Drugs Market 2017-2021 / IRTNTR14695)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆